408 related articles for article (PubMed ID: 32882428)
1. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
[TBL] [Abstract][Full Text] [Related]
3. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
[TBL] [Abstract][Full Text] [Related]
4. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
6. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.
Kim BK; Bernstein N; Huang DQ; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
Aliment Pharmacol Ther; 2023 Jul; 58(2):229-237. PubMed ID: 37269117
[TBL] [Abstract][Full Text] [Related]
8. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
11. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials.
Nedrud MA; Chaudhry M; Middleton MS; Moylan CA; Lerebours R; Luo S; Farjat A; Guy C; Loomba R; Abdelmalek MF; Sirlin CB; Bashir MR
Radiology; 2023 Mar; 306(3):e220743. PubMed ID: 36318027
[TBL] [Abstract][Full Text] [Related]
12. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
[TBL] [Abstract][Full Text] [Related]
14. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
[TBL] [Abstract][Full Text] [Related]
15. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
Jiang H; Chen HC; Lafata KJ; Bashir MR
Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
[TBL] [Abstract][Full Text] [Related]
16. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
Shen W; Middleton MS; Cunha GM; Delgado TI; Wolfson T; Gamst A; Fowler KJ; Alazraki A; Trout AT; Ohliger MA; Shah SN; Bashir MR; Kleiner DE; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Zhou J; Sirlin CB; Lavine JE
J Hepatol; 2023 Feb; 78(2):238-246. PubMed ID: 36368598
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Caussy C; Reeder SB; Sirlin CB; Loomba R
Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
[TBL] [Abstract][Full Text] [Related]
19. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
20. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
Han MAT; Altayar O; Hamdeh S; Takyar V; Rotman Y; Etzion O; Lefebvre E; Safadi R; Ratziu V; Prokop LJ; Murad MH; Noureddin M
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):616-629.e26. PubMed ID: 29913275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
